0000000000116670

AUTHOR

Gilda Cennamo

showing 14 related works from this author

Internal limiting membrane peeling versus no peeling during primary vitrectomy for rhegmatogenous retinal detachment: A systematic review and meta-an…

2018

Background Internal limiting membrane (ILM) peeling during primary vitrectomy for rhegmatogenous retinal detachment (RRD) prevents the formation of postoperative macular epiretinal membrane (ERM). However, studies that compared vitrectomy with and without ILM peeling for RRD, have reported controversial outcomes. Objective To assess the efficacy of ILM peeling versus non-ILM peeling during vitrectomy for RRD by a systematic review and meta-analysis of published studies. Methods PubMed, Medline, Web of Science, Embase databases, and the Cochrane Library were searched up to April 2018 to identify studies that compared primary vitrectomy with and without ILM peeling for RRD with at least six m…

Genetics and Molecular Biology (all)Visual acuitygenetic structuresVisionmedicine.medical_treatmentVisual Acuitylcsh:MedicineSocial SciencesVitrectomyBiochemistrylaw.inventionDatabase and Informatics Methods0302 clinical medicineMathematical and Statistical TechniquesPostoperative ComplicationsRandomized controlled trialBiochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)lawVitrectomyMedicine and Health SciencesPsychology030212 general & internal medicineDatabase Searchinglcsh:ScienceMultidisciplinaryOphthalmic ProceduresRetinal detachmentEpiretinal MembraneResearch AssessmentMeta-analysisPhysical SciencesRetinal DisordersSensory PerceptionEpiretinal membranemedicine.symptomAnatomyStatistics (Mathematics)HumanResearch Articlemedicine.medical_specialtySystematic ReviewsSurgical and Invasive Medical ProceduresResearch and Analysis Methods03 medical and health sciencesOcular SystemOphthalmologymedicineHumansStatistical MethodsBiochemistry Genetics and Molecular Biology (all)Primary vitrectomybusiness.industryInternal limiting membranelcsh:RRetinal DetachmentBiochemistry; Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Biology and Life Sciencesmedicine.diseaseeye diseasesbody regionsOphthalmologyAgricultural and Biological Sciences (all)030221 ophthalmology & optometryEyeslcsh:QPostoperative Complicationsense organsbusinessHeadMathematicsMeta-AnalysisNeuroscience
researchProduct

Fluocinolone acetonide vitreous insert for chronic diabetic macular oedema: a systematic review with meta-analysis of real-world experience

2021

AbstractWe conducted a meta-analysis of real-world studies on the 0.19 mg Fluocinolone Acetonide (FAc) intravitreal implant for chronic diabetic macular oedema (DMO), comparing these findings with the Fluocinolone Acetonide for Diabetic Macular Edema (FAME) study. The primary outcome was mean change of best corrected visual acuity (BCVA) at 24 months. Secondary outcomes were 36-month mean BCVA, mean central macular thickness (CMT) change, rates of eyes receiving supplementary intravitreal therapy, cataract surgery, intraocular pressure (IOP)-lowering drops and glaucoma surgery. Mean differences (MDs) with 95% confidence intervals (CIs) were calculated. Nine real-world studies were included.…

medicine.medical_specialtyIntraocular pressuregenetic structuresSciencemedicine.medical_treatmentAnti-Inflammatory AgentsArticleMacular Edema03 medical and health sciences0302 clinical medicineDiabetes complicationsFluocinolone acetonideOphthalmologymedicineGlaucoma surgeryHumans030212 general & internal medicineGlucocorticoidsIntraocular PressureDrug ImplantsDiabetic RetinopathyMultidisciplinarybusiness.industryQRCataract surgeryRetinal diseaseseye diseasesConfidence intervalFluocinolone AcetonideDiabetic macular oedemaMeta-analysis030221 ophthalmology & optometryMedicinesense organsImplantbusinessmedicine.drugScientific Reports
researchProduct

Primary vitrectomy for degenerative and tractional lamellar macular holes: A systematic review and meta-analysis

2021

Purpose To assess the efficacy of vitrectomy in degenerative and tractional lamellar macular holes (LMHs) by meta-analysis of published studies. Methods PubMed, Medline and Embase databases were searched up to May 2020. Included cohorts were divided into three groups: degenerative LMH group, lamellar hole associated epiretinal proliferation (LHEP) group and tractional LMH group. LHEP is likely to be associated with degenerative LMHs, but less commonly could be associated with mixed LMHs. To reduce risk of possible misclassification bias, eyes with LHEP which could not have been precisely classified by the authors, were included into the LHEP group. The primary outcome was to investigate th…

0301 basic medicineVisual acuitygenetic structuresVisionmedicine.medical_treatmentVisual AcuitySocial SciencesVitrectomyDatabase and Informatics MethodsMathematical and Statistical Techniques0302 clinical medicineVitrectomyMedicine and Health SciencesPsychologyMedicineDatabase SearchingMacular holeMultidisciplinaryIncidence (epidemiology)StatisticsQOphthalmic ProceduresRMetaanalysisResearch AssessmentMeta-analysisPhysical SciencesMedicineSensory PerceptionAnatomymedicine.symptomResearch Articlemedicine.medical_specialtySystematic ReviewsScienceSurgical and Invasive Medical ProceduresResearch and Analysis Methods03 medical and health sciencesOcular SystemOphthalmologyHumansStatistical Methodsbusiness.industryPrimary vitrectomyCognitive PsychologyBiology and Life SciencesHumans; Retinal Perforations; Visual Acuity; VitrectomyRetinal Perforationsmedicine.diseaseConfidence intervaleye diseases030104 developmental biology030221 ophthalmology & optometryCognitive ScienceEyesPerceptionVisual gainbusinessHeadMathematicsNeuroscience
researchProduct

Intravitreal anti-vascular endothelial growth factors, panretinal photocoagulation and combined treatment for proliferative diabetic retinopathy: a s…

2020

Purpose: to conduct a systematic review with network meta‐analysis (NMA) of randomized clinical trials (RCTs) comparing panretinal photocoagulation (PRP) versus anti‐vascular endothelial growth factor (VEGF) treatment alone or in combination with PRP, for proliferative diabetic retinopathy (PDR).Methods: PubMed, Medline and Embase databases were searched for RCTs comparing PRP versus intravitreal anti‐VEGF therapy and/or combined PRP and intravitreal anti‐VEGF for PDR. The primary outcome measures were the mean best corrected visual acuity (BCVA) change and the regression of neovascularization. Mean change of central macular thickness (CMT), the subgroup analyses of patients without diabeti…

medicine.medical_specialtyBevacizumabgenetic structurespegaptanibmedicine.medical_treatmentPegaptanibNetwork Meta-AnalysisVisual AcuityVitrectomyAngiogenesis Inhibitorsbevacizumablaw.inventionNeovascularization03 medical and health sciences0302 clinical medicineRandomized controlled trialaflibercept; bevacizumab; intravitreal anti-VEGF; panretinal photocoagulation; pegaptanib; proliferative diabetic retinopathy; ranibizumabintravitreal anti-VEGFlawOphthalmologyVitrectomymedicineHumansranibizumabAfliberceptDiabetic RetinopathyLaser Coagulationbusiness.industryafliberceptGeneral MedicineDiabetic retinopathymedicine.diseasepanretinal photocoagulationeye diseasesOphthalmologyIntravitreal Injections030221 ophthalmology & optometrysense organsRanibizumabmedicine.symptombusiness030217 neurology & neurosurgerymedicine.drugproliferative diabetic retinopathy
researchProduct

Intravitreal dexamethasone implant one month before versus concomitant with cataract surgery in patients with diabetic macular oedema: the dexcat stu…

2020

Purpose: To report clinical outcomes of two different timings of intravitreal dexamethasone (DEX) implant administration for prevention of diabetic macular oedema (DME) worsening following cataract surgery. Methods: This multicentre, retrospective study included patients with DME who received an intravitreal DEX implant 1 month before cataract surgery, ‘precataract DEX’ group, or at the time of cataract surgery, ‘concomitant treatments’ group. Inclusion criteria were a follow-up ≥3 months and ophthalmological examination with optical coherence tomography (OCT) imaging at baseline (cataract surgery) and throughout follow-up. Anatomical improvement was considered to be a decrease in OCT centr…

MaleTime FactorsVisual acuitygenetic structuresmedicine.medical_treatmentVisual AcuityDexamethasone0302 clinical medicinedexamethasone implantDrug Implantsdiabetescataract surgeryGeneral MedicineTreatment Outcomediabetic macular oedemaIntravitreal InjectionsFemalecataract surgery; dexamethasone implant; diabetes; diabetic macular oedemamedicine.symptomTomography Optical Coherencemedicine.drugmedicine.medical_specialtyCataract ExtractionCataractMacular Edema03 medical and health sciencesOphthalmologyDiabetes mellitusmedicineHumansAdverse effectGlucocorticoidsDexamethasoneAgedRetrospective StudiesDiabetic RetinopathySettore MED/30 - Malattie Apparato Visivobusiness.industryRetrospective cohort studyCataract surgerymedicine.diseaseeye diseasesOphthalmologydiabeteConcomitant030221 ophthalmology & optometryImplantbusiness030217 neurology & neurosurgeryFollow-Up StudiesActa Ophthalmologica
researchProduct

Efficacy of Three Different Prophylactic Treatments for Postoperative Nausea and Vomiting after Vitrectomy: A Randomized Clinical Trial

2019

Postoperative nausea and vomiting (PONV) after vitreoretinal surgery may potentially be associated with severe complications, such as suprachoroidal hemorrhage. The purpose of the present multicenter clinical trial (NCT02386059) was to assess the efficacy of three different prophylactic treatments for PONV after vitrectomy under local anesthesia. Patients undergoing primary vitrectomy were randomized to the control arm or to one of the treatment arms (4 mg ondansetron, 4 mg dexamethasone, combination of the two drugs). The primary outcome measure was the proportion of complete response (no nausea, no vomiting, no retching, and no use of antiemetic rescue medication) during 24 h after vitrec…

Nauseamedicine.drug_classvitrectomylcsh:Medicinepostoperative nausea and vomitingdexamethasoneArticlelaw.inventionOndansetron03 medical and health sciences0302 clinical medicineRandomized controlled trial030202 anesthesiologylawmedicineAntiemeticRetchingLocal anesthesiabusiness.industrylcsh:RGeneral MedicineondansetronAnesthesia030221 ophthalmology & optometryVomitingdexamethasone; ondansetron; postoperative nausea and vomiting; vitrectomymedicine.symptombusinessPostoperative nausea and vomitingmedicine.drug
researchProduct

Retinal Vascular Assessment in Psoriasis: A Multicenter Study

2021

PurposeTo investigate the vascular status of the macula in psoriasis patients without history of ocular inflammation by Optical Coherence Tomography Angiography (OCTA).MethodsThis prospective cross-sectional multicenter study included 55 psoriasis patients and 55 control healthy subjects. A complete eye examination and 6 mm × 6 mm OCTA imaging were performed. Retinal vascular status was evaluated by analyzing vascular density (VD) of superficial vascular plexus (superficial wVD) and deep vascular plexuses (deep wVD) in a 6 mm × 6 mm area and in foveal (superficial fVD and deep fVD) and parafoveal sectors (superficial pVD and deep pVD). In addition, foveal thickness (FT) and foveal avascular…

retinaIntraocular pressuremedicine.medical_specialtyvascular changesgenetic structuresmacula; optical coherence tomography angiography; psoriasis; retina; vascular changesoptical coherence tomography angiographylcsh:RC321-571030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compoundPsoriatic arthritis0302 clinical medicineOphthalmologyPsoriasisMedicinemaculalcsh:Neurosciences. Biological psychiatry. NeuropsychiatrypsoriasiOriginal ResearchRetinamedicine.diagnostic_testbusiness.industryGeneral NeuroscienceRetinalpsoriasisOptical coherence tomography angiographymedicine.diseaseeye diseasesmedicine.anatomical_structurechemistryMulticenter studyEye examination030221 ophthalmology & optometrysense organsbusinessNeuroscienceFrontiers in Neuroscience
researchProduct

Delayed Suprachoroidal Hemorrhage After Pars Plana Vitrectomy: Five-Year Results of a Retrospective Multicenter Cohort Study

2015

Purpose To determine the incidence, risk factors, and outcomes of delayed suprachoroidal hemorrhage after vitrectomy. Design Retrospective multicenter cohort study. Methods All consecutive patients who underwent primary vitrectomy, from January 2009 to December 2014, at 4 tertiary vitreoretinal centers in Italy were enrolled. Patient demographics and systemic, ophthalmic, operative, and postoperative data from all centers were extracted from the electronic record system using standardized data collection forms. All eyes that developed delayed suprachoroidal hemorrhage within 48 hours of the end of the vitrectomy were identified as the delayed suprachoroidal hemorrhage group; all other eyes …

Pars planaChoroid HemorrhageMalemedicine.medical_specialtyTime FactorsTime FactorFundus Oculimedicine.medical_treatmentVitrectomyPostoperative HemorrhageChoroid hemorrhageFollow-Up StudieRetrospective StudieRisk FactorsOphthalmologyVitrectomymedicineHumansFluorescein AngiographyAgedRetrospective Studiesmedicine.diagnostic_testbusiness.industryRisk FactorRetinal DetachmentRetinal detachmentRetrospective cohort studyOdds ratioMiddle AgedFluorescein angiographymedicine.diseaseSurgeryOphthalmologymedicine.anatomical_structureFemalebusinessHumanCohort studyFollow-Up Studies
researchProduct

Intravitreal dexamethasone implant versus anti-vascular endothelial growth factor therapy combined with cataract surgery in patients with diabetic ma…

2021

Objective: to compare outcomes of cataract surgery combined with either anti-Vascular Endothelial Growth Factor (anti-VEGF) therapy or dexamethasone implant (DEX) in patients with diabetic macular oedema (DMO). Methods: Pubmed and Embase databases were searched for studies reporting outcomes of diabetic cataract surgery combined with either anti-VEGF or DEX, with a follow-up ≥3 months. The primary outcome was the mean change in central macular thickness (CMT). Mean change in best corrected visual acuity (BCVA) was considered as a secondary outcome. The mean difference between baseline and post-treatment values (MD) with 95%-Confidence Interval (95%CI) was calculated and meta-analyses were p…

Vascular Endothelial Growth Factor Amedicine.medical_specialtygenetic structuresmedicine.medical_treatmentVisual AcuityEndothelial Growth FactorsMacular EdemaDexamethasoneCataractOphthalmologyDiabetes MellitusHumansMedicineIn patientDexamethasoneDiabetic Retinopathybusiness.industryDEXcataract surgeryCataract surgeryDiabetic cataractBevacizumabOphthalmologyAnti–vascular endothelial growth factor therapyDiabetic macular oedemaanti-VEGFdiabetic macular oedemaMeta-analysissense organsImplantbusinessmedicine.drugEye
researchProduct

LATE-ONSET OCULAR HYPERTENSION AFTER VITRECTOMY: A Multicenter Study of 6,048 Eyes

2018

Purpose: To determine the incidence and risk factors for late-onset ocular hypertension (LOH) after vitrectomy. Methods: From the electronic medical records of consecutive patients who underwent primary vitrectomy, from January 2010 to December 2015, at 5 tertiary vitreoretinal centers in Italy, patient demographics, systemic, ophthalmic, operative, and postoperative data were drawn. Main outcome measure was the presence of LOH, defined as intraocular pressure >21 mmHg detected more than 2 months after vitrectomy on at least 2 consecutive visits. Results: Among 6,048 patients, LOH was found in 294 (4.9%) vitrectomized eyes and in 87 (1.4%) fellow eyes, (chi square; P < 0.001). Multiva…

MalePediatricsmedicine.medical_specialtyTime Factorsmedicine.medical_treatmentMEDLINEOcular hypertensionVitrectomyLate onset01 natural sciences03 medical and health sciences0302 clinical medicineRetinal DiseasesRisk FactorsVitrectomyHumansMedicineIntraocular PressureAgedRetrospective Studiesbusiness.industryIncidenceMedical recordIncidence (epidemiology)Retrospective cohort studyGeneral Medicinemedicine.disease0104 chemical sciences010404 medicinal & biomolecular chemistryOphthalmologyItalyMulticenter study030221 ophthalmology & optometryFemaleOcular Hypertensionbusinesslate-onset ocular hypertensionFollow-Up Studies
researchProduct

Intravitreal Dexamethasone Implant for Postoperative Macular Oedema Secondary to Vitrectomy for Epiretinal Membrane and Retinal Detachment: A Systema…

2021

Purpose. To evaluate the efficacy of intravitreal dexamethasone implant (DEX) for the treatment of macular oedema secondary to vitrectomy for epiretinal membrane (ERM) and retinal detachment (RD) by conducting a systematic review with meta-analysis of published studies. Methods. Studies reporting clinical outcomes of DEX use for the treatment of macular oedema secondary to ERM and RD vitrectomy were searched on PubMed and Embase databases. The primary outcome was best-corrected visual acuity (BCVA) change between baseline and post-DEX treatment, reported as mean difference (MD) with 95% confidence interval (CI). Mean central macular thickness (CMT) change was assessed as a secondary outcome…

medicine.medical_specialtyVisual acuitygenetic structuresmedicine.medical_treatmentPopulationVitrectomyReview Articlelaw.inventionRandomized controlled triallawOphthalmologymedicineeducationDexamethasoneeducation.field_of_studybusiness.industryRetinal detachmentRE1-994medicine.diseaseConfidence intervalmacular oedema intravitreal dexamethasone implant (DEX) vitrectomy epiretinal membrane (ERM) retinal detachment (RD).OphthalmologyEpiretinal membranemedicine.symptombusinessmedicine.drug
researchProduct

Treat and extend versus fixed regimen in neovascular age related macular degeneration: A systematic review and meta-analysis

2020

Purpose: To compare efficacy of treat and extend (T&E) versus fixed regimen treatment protocols in neovascular age-related macular degeneration (nAMD). Methods: Randomized clinical trials (RCTs) comparing T&E versus fixed regimen protocols for nAMD were systematically searched. Primary outcome was to compare the mean best corrected visual acuity (BCVA) change in T&E regimen versus fixed regimen. Secondary outcomes were change in the mean optical coherence tomography (OCT) central retinal thickness (CRT) and mean number of injections. Standardized mean difference (SMD) along with 95% confidence intervals (CIs) were calculated. Random-effect models were used for meta-analyses. Res…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyretinaretinal pathology/researchVisual AcuityAngiogenesis InhibitorsTreat and extendlaw.inventionMacular DegenerationRandomized controlled trialClinical Protocolsretina – medical therapieslawInternal medicineAge relatedRanibizumabMedicineHumansbusiness.industryAge-related macular degenerationGeneral MedicineMacular degenerationpediatric ophthalmologyretina – medical therapiemedicine.diseaseOphthalmologyRegimenTreatment OutcomeMeta-analysisvitreous/retinal diseaseIntravitreal InjectionsWet Macular DegenerationPediatric ophthalmologypharmacologybusinessTomography Optical CoherenceAge-related macular degeneration; pediatric ophthalmology; pharmacology; retina; retina – medical therapies; retinal pathology/research; vitreous/retinal disease
researchProduct

Association of neovascular age-related macular degeneration with month and season of birth in Italy

2016

In order to investigate the influence of season and month of birth on the risk of neovascular age-related macular degeneration (n-AMD) in Italy, we evaluated the month birth and sex of all patients, recorded in the anti-vascular endothelial growth factor (VEGF) monitoring registry of the Italian Medicines Agency, born between 1925-1944, who received intravitreal anti-VEGF injections for n-AMD between January 1, 2013 and July 29, 2015. The numbers of all births in Italy in the same years, extracted from the Italian National Institute of Statistics, were used to calculate the expected number of n-AMD cases. Overall, 45,845 patients (19,207 men, 26,638 women) received intravitreal anti-VEGF fo…

MaleVascular Endothelial Growth Factor AAginggenetic structuresMonth of birthVEGF receptorsneovascular AMDAngiogenesis InhibitorsAptamersMacular Degeneration0302 clinical medicineSeason of birthReceptors80 and overMedicineRegistriesAged 80 and overNeovascularization PathologicbiologyVascular Endothelial Growth FactorIncidenceIncidence (epidemiology)Aptamers NucleotideBevacizumabTreatment OutcomeItalyanti-VEGFFemaleSeasonsNucleotideNeovascular age-related macular degenerationResearch Papermedicine.drugAnti-VEGF; Month of birth; Neovascular age-related macular degeneration; Neovascular AMD; Season of birth; Aged; Aged 80 and over; Angiogenesis Inhibitors; Aptamers Nucleotide; Bevacizumab; Female; Humans; Incidence; Italy; Macular Degeneration; Male; Neovascularization Pathologic; Ranibizumab; Receptors Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Registries; Treatment Outcome; Vascular Endothelial Growth Factor A; Seasons; Aging; Cell BiologySeason of birthBevacizumabRecombinant Fusion ProteinsNeovascular AMDneovascular age-related macular degeneration03 medical and health sciencesRanibizumabAge relatedHumansNeovascularizationAgedPathologicseason of birthbusiness.industrymonth of birthAnti-VEGFCell BiologyMacular degenerationmedicine.diseaseeye diseasesanti-VEGF; month of birth; neovascular AMD; neovascular age-related macular degeneration; season of birthReceptors Vascular Endothelial Growth Factor030221 ophthalmology & optometrybiology.proteinsense organsRanibizumabbusinessMonth of birth030217 neurology & neurosurgeryDemographyAging
researchProduct

Supplementary_material – Supplemental material for Treat and extend versus fixed regimen in neovascular age related macular degeneration: A systemati…

2020

Supplemental material, Supplementary_material for Treat and extend versus fixed regimen in neovascular age related macular degeneration: A systematic review and meta-analysis by Matteo Fallico, Andrew J Lotery, Antonio Longo, Teresio Avitabile, Vincenza Bonfiglio, Andrea Russo, Nicolò Castellino, Guglielmo Parisi, Alfredo Pulvirenti, Chiara Eandi, Gilda Cennamo, Claudio Furino, Maria Vittoria Cicinelli, Camilla Alovisi and Michele Reibaldi in European Journal of Ophthalmology

Medicine
researchProduct